Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma

Haematologica

Volumn 91, Issue 3, 2006, Pages 425-426

  De Guibert, Sophie ^a   Jaccard, Arnaud ^b   Bernard, Marc ^a   Turlure, Pascale ^b   Bordessoule, Dominique ^b   Lamy, Thierry ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^b LIMOGES UNIVERSITY HOSPITAL   (France)

Author keywords

Autologous stem cell transplantation; High dose aracytine; Mantle cell lymphoma; Rituximab

Indexed keywords

2,4' DIHYDROXYACETOPHENONE DIOXYGENASE; DIOXYGENASE; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MIXTURE; DRUG TOLERANCE; FEMALE; HUMAN; MALE; MANTLE CELL LYMPHOMA; STEM CELL TRANSPLANTATION;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CYTARABINE; DEXAMETHASONE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS;

EID: 33645389486     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Weisenburger DD, Armitage JO. Mantle cell lymphoma - an entity comes of age. Blood 1996;87:4483-94.
2. Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998;16:3803-9.
3. Khouri IF, Saliba RM, Okoroji GJ, Acholonu SA, Champlin RE. Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of β2-microglobulin and the tumor score. Cancer 2003;98:2630-5.
4. Lefrere F, Delmer A, Levy V, Delarue R, Varet B, Hermine O. Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study. Haematologica 2004;89:1275-6.
5. Howard OM, Gribben JG, Neuberg DS, Grossbard M, Poor C, Janicek MJ, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002;20:1288-94
6. Gianni AM, Magni M, Martelli M, Di Nicola M, Carlo-Stella C, Pilotti S, et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 2003;102:749-55.
7. Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005;23:7013-23.
8. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005;23:667-75.
9. Delarue R, Haioun C, Delnmer A, Ribrag V, Van Hoof A, et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL): a pilot study from the GELA. J Clin Oncol 2004;22:14S, Abstract 6529.